An exploratory proposal for a revision to the 14-day rule in the regulatory context of China
Cell Stem Cell · 2025
DOI: 10.1016/j.stem.2025.10.013 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Stem Cell, 2025. Verfasst von Tao Tan und 5 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Primate Biomedical Research, Institute of Primate Translational Medicine, Kunming University of Science and Technology, Kunmi…. Hauptthemen laut MEDLINE: Stem Cell Research, Embryo Research. Die Arbeit nennt 9 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- State Key Laboratory of Primate Biomedical Research, Institute of Primate Translational Medicine, Kunming University of Science and Technology, Kunming 650500, Yunnan, China.
- Institutes of Science and Development, Chinese Academy of Sciences, Beijing 100190, China.
- State Key Laboratory of Organ Regeneration and Reconstruction, Institute of Zoology, Chinese Academy of Sciences, Beijing 100101, China. Electronic address: wanghm@ioz.ac.cn.
- State Key Laboratory of Primate Biomedical Research, Institute of Primate Translational Medicine, Kunming University of Science and Technology, Kunming 650500, Yunnan, China. Electronic address: wji@lpbr.cn.
Zitieren
APA
Tan, T., Lu, X., Li, T., Wei, J., Wang, H., & Ji, W. (2025). An exploratory proposal for a revision to the 14-day rule in the regulatory context of China. Cell Stem Cell. https://doi.org/10.1016/j.stem.2025.10.013
Vancouver
Tan T, Lu X, Li T, Wei J, Wang H, Ji W. An exploratory proposal for a revision to the 14-day rule in the regulatory context of China. Cell Stem Cell. 2025. doi:10.1016/j.stem.2025.10.013
BibTeX
@article{Tan2025,
author = {Tan, Tao and Lu, Xiao and Li, Tianqing and Wei, Jingkuan and Wang, Hongmei and Ji, Weizhi},
title = {An exploratory proposal for a revision to the 14-day rule in the regulatory context of China},
journal = {Cell Stem Cell},
year = {2025},
doi = {10.1016/j.stem.2025.10.013}
}
EUVIMED